Comparative Pharmacology
Head-to-head clinical analysis: EXEMESTANE versus FEMARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXEMESTANE versus FEMARA.
EXEMESTANE vs FEMARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible steroidal aromatase inhibitor; binds to the substrate-binding site of aromatase, causing permanent inactivation of the enzyme. Reduces estrogen synthesis by inhibiting conversion of androgens to estrogens.
Aromatase inhibitor; inhibits the conversion of androgens to estrogens by competitively binding to the aromatase enzyme, thereby reducing estrogen levels in peripheral tissues and tumors.
25 mg orally once daily after a meal.
2.5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing. Steady state is achieved after 7 days.
Clinical Note
moderateExemestane + Digoxin
"Exemestane may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateExemestane + Digitoxin
"Exemestane may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateExemestane + Deslanoside
"Exemestane may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateExemestane + Acetyldigitoxin
"Exemestane may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of letrozole is approximately 2 days (range 24–48 hours). Steady-state concentrations are achieved within 2–6 weeks of daily dosing. The long half-life supports once-daily dosing.
Primarily hepatic metabolism (CYP3A4 and aldoketoreductases) with fecal excretion of metabolites (approximately 80-90%) and renal excretion of unchanged drug and metabolites (approximately 10-20%).
Letrozole is extensively metabolized in the liver, primarily to an inactive carbinol metabolite. Approximately 90% of an oral dose is excreted in urine, with about 6% as unchanged drug and 84% as metabolites. Fecal excretion accounts for less than 10%.
Category D/X
Category C
Aromatase Inhibitor
Aromatase Inhibitor